Earlier this week, Bell Potter named NEU as one of its top pick ASX shares to buy this month.
When selecting top picks, Bell Potter says it considers the current macro-economic backdrop and investment environment and focuses on quality companies with proven track records, capable management, and competitive advantages.
Neuren Pharmaceuticals is a biotech company that is well-funded via its first asset, DAYBUE, which is an FDA approved trofinetide for the treatment of Rett syndrome. NEU's value is from its second asset, NNZ-2591, which is under development for rare diseases. NNZ-2591, if successful, could lead to a significant increase in revenue and earnings when brought to market. NEU looks attractive on a risk/adjusted basis after the recent sell-off.
Earlier this week, Bell Potter named NEU as one of its top pick...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.30 |
Change
0.760(4.59%) |
Mkt cap ! $2.211B | |||
| Open | High | Low | Value | Volume |
| $17.35 | $17.94 | $17.25 | $17.64M | 1.010M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 2533 | $17.30 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.45 | 1254 | 1 |
View Market Depth
| Last trade - 16.10pm 14/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |